Stago Launches Fully Automated STA®- ECA II Assay for Dabigatran (Pradaxa®) Measurement

Diagnostica Stago, Inc. expands its offering for measurement of direct oral anticoagulants (DOACs) with the launch of its next generation ecarin-based chromogenic assay for dabigatran, STA®- ECA II. With this addition, Stago is proud to offer the only complete portfolio of assays for measurement of DOACs. Fully automated with barcoded loading on Stago’s high throughput analyzers, STA® - ECA II enables laboratories an efficient and standardized approach to measure dabigatran in plasma samples. STA® - ECA II is labeled for research use only (not for use in diagnostic procedures), along with the associated dabigatran calibrators and controls.

STA® - ECA II is a highly-specific tool for directly measuring dabigatran (Pradaxa®) concentration in plasma and is insensitive to lupus anticoagulants and heparin along with coagulation factor and fibrinogen levels. With a wide working range of 15 – 460 ng/mL and 28 day, 2-8°C stability, Stago’s STA® - ECA II is flexible for a variety of sample testing requirements.

Compared to liquid chromatography-mass spectrometry (LC-MS)-based methods, STA® - ECA II demonstrates excellent correlation for measurement of total dabigatran (Pradaxa®) concentrations. The STA® - ECA II provides confidence in results across the entire measurement range, with an advantage over other methods, especially for samples with low concentrations.

The STA® - ECA II kit (catalog number 01108), along with the STA®- Dabigatran Calibrator (catalog number 01109) and STA®- Dabigatran Control (catalog number 01110) products are labeled for research use only in the United States and Canada, and are not for use in diagnostic procedures.